HCPLive Network
Latest Oncology Headlines
Tuesday, September 16, 2014
For patients with advanced esophageal cancer, dysphagia is improved with radiotherapy alone, according to a study presented at the annual meeting of the American Society for Radiation Oncology, held from Sept. 14 to 18 in San Francisco.
Tuesday, September 16, 2014
For patients with high-risk prostate cancer, testosterone recovery is shorter for patients receiving 18 months versus 36 months of androgen deprivation therapy, and is associated with improved quality of life, according to a study presented at the annual meeting of the American Society for Radiation Oncology, held from Sept. 14 to 18 in San Francisco.
Tuesday, September 16, 2014
More than one-quarter of hospital medicine services were rated by ordering physicians as at least a partially defensive order, according to a research letter published online Sept. 15 in JAMA Internal Medicine.
Tuesday, September 16, 2014
Men with male pattern baldness may face a higher risk of developing an aggressive type of prostate cancer than men with no balding, according to a study published online Sept. 15 in the Journal of Clinical Oncology.
Tuesday, September 16, 2014
Adding chest radiation to chemotherapy allows some people with small-cell lung cancer to live longer and cuts recurrence rates by nearly 50%, European researchers report. The research was published online Sept. 14 in The Lancet to coincide with presentation at the annual meeting of the American Society for Radiation Oncology, held from Sept. 14 to 18 in San Francisco.
Monday, September 15, 2014
Neither parents' nor adolescents' knowledge about human papillomavirus vaccines predicts vaccination compliance, according to a study published online Sept. 15 in Pediatrics.
Monday, September 15, 2014
Watchful waiting may not be suitable for all men with early-stage prostate cancer, especially black patients, according to research published in Urologic Oncology.
Monday, September 15, 2014
Errata, including those that may materially change the interpretation of data, are frequent in medical publications, according to a study published in the August issue of The American Journal of Medicine.
Monday, September 15, 2014
The new consumer retail market in U.S. healthcare is necessary and will benefit consumers, and as consumers take on more costs of care, access to information to help them make informed decisions is crucial, according to a recent white paper published by Vitals.
Sunday, September 14, 2014
By Maurie Markman, MD
Oncologists Need Guideposts for Recommending Drugs Not Studied in Cancers
Saturday, September 13, 2014
By Andrew J. Roth
To gain further insight into the approval of pembrolizumab, OncLive interviewed John Glaspy, MD, MPH, from the Jonsson Comprehensive Cancer Center at UCLA, where research into the novel drug was conducted.
Friday, September 12, 2014
By Silas Inman
The combination of ramucirumab and FOLFIRI significantly improved OS and PFS compared with chemotherapy alone as a second-line treatment for patients with mCRC.
Friday, September 12, 2014
Revelations About Cancer Mutations Predate Technological Advances
Friday, September 12, 2014
Individuals aged 65 to 74 years with a history of smoking should not be excluded from screening with low-dose computed tomography for lung cancer, according to researchers who published their study findings online Sept. 9 in the Annals of Internal Medicine.
Friday, September 12, 2014
By Beth Fand Incollingo
Experts Touch On Oncotype DX, Other Assays During Peer Exchange
Thursday, September 11, 2014
By Maurie Markman, MD
How can a conscientious but very busy practitioner keep up with the massive quantity of molecular data that could potentially impact an individual patient with cancer? The Moores Cancer Center at the University of California, San Diego has updated the tumor board concept for the molecular era.
Thursday, September 11, 2014
By E. David Crawford, MD, Neal D. Shore, MD, and Karen H. Ventii, PhD
Although prostate cancer (PC) is the most common solid tumor malignancy among men in the Western Hemisphere, disease-specific mortality remains low, primarily due to optimized screening, diagnosis, and treatment.
Wednesday, September 10, 2014
By Silas Inman
The FDA has expanded the approval for enzalutamide to include the treatment of men with chemotherapy-naive metastatic castration-resistant prostate cancer.
Wednesday, September 10, 2014
By Philip Friedlander, MD, PhD
It is estimated that in 2014 more than 76,000 people will be diagnosed with melanoma and approximately 9700 people will die from the malignancy.
Wednesday, September 10, 2014
Terence Friedlander, MD, specializes in understanding the basic biology of genitourinary cancer, in particular cancer of the bladder and prostate, in developing new treatments and studying new ways to overcome treatment resistance.
Physician's Money Digest
American hospitals reported 38.6 million stays in 2011 and in 24.3 million of those visits, some type of medical procedure was performed (often multiple procedures).
A new study finds narrow health networks can help reduce healthcare costs without impacting the quality of care patients receive.